These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
118 related items for PubMed ID: 11091779
1. Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. The MANIF 2000 Study Group. Reynaud-Maurupt C, Carrieri MP, Gastaud JA, Pradier C, Obadia Y, Moatti JP. AIDS Care; 2000 Aug; 12(4):461-70. PubMed ID: 11091779 [Abstract] [Full Text] [Related]
2. Profiles of self-reported HIV-risk behaviors among injection drug users in methadone maintenance treatment, detoxification, and needle exchange programs. Mark HD, Nanda J, Davis-Vogel A, Navaline H, Scotti R, Wickrema R, Metzger D, Sochalski J. Public Health Nurs; 2006 Aug; 23(1):11-9. PubMed ID: 16460416 [Abstract] [Full Text] [Related]
3. A cross-sectional study on factors including HIV testing and counselling determining unsafe injecting practices among injecting drug users of Manipur. Sarkar S, Panda S, Sarkar K, Hangzo CZ, Bijaya L, Singh NY, Das N, Agarwal A, Chatterjee A, Deb BC. Indian J Public Health; 1995 Aug; 39(3):86-92. PubMed ID: 8690497 [Abstract] [Full Text] [Related]
5. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner JS. Drug Alcohol Depend; 2006 Sep 15; 84(2):188-94. PubMed ID: 16542797 [Abstract] [Full Text] [Related]
6. [Risk reduction and intravenous drug use abstinence in patients with HIV infection. The SEROCO group]. Meyer L, Wade A, Persoz A, Boué F, Dellamonica P, Caroli-Bosc C, Carré N. Rev Epidemiol Sante Publique; 1998 Feb 15; 46(1):34-9. PubMed ID: 9533232 [Abstract] [Full Text] [Related]
7. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Emmanuelli J, Desenclos JC. Addiction; 2005 Nov 15; 100(11):1690-700. PubMed ID: 16277629 [Abstract] [Full Text] [Related]
8. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, Spire B, MANIF2000 cohort study group. Addiction; 2008 Nov 15; 103(11):1828-36. PubMed ID: 18778390 [Abstract] [Full Text] [Related]
9. Injecting misuse of buprenorphine among French drug users. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Addiction; 2001 Feb 15; 96(2):267-72. PubMed ID: 11182872 [Abstract] [Full Text] [Related]
10. Targeting HIV-related outcomes with intravenous drug users maintained on methadone: a randomized clinical trial of a harm reduction group therapy. Avants SK, Margolin A, Usubiaga MH, Doebrick C. J Subst Abuse Treat; 2004 Mar 15; 26(2):67-78. PubMed ID: 15050083 [Abstract] [Full Text] [Related]
11. Safe sex? Misconceptions, gender differences and barriers among injection drug users: a focus group approach. Weiss SH, Weston CB, Quirinale J. AIDS Educ Prev; 1993 Mar 15; 5(4):279-93. PubMed ID: 8297708 [Abstract] [Full Text] [Related]
12. The relative risk of HIV among IDUs not in treatment in Malaysia. Vicknasingam B, Narayanan S, Navaratnam V. AIDS Care; 2009 Aug 15; 21(8):984-91. PubMed ID: 20024754 [Abstract] [Full Text] [Related]
13. A longitudinal investigation into excess risk for blood-borne infection among young injection drug users (IUDs). Miller CL, Strathdee SA, Li K, Kerr T, Wood E. Am J Drug Alcohol Abuse; 2007 Aug 15; 33(4):527-36. PubMed ID: 17668338 [Abstract] [Full Text] [Related]
14. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Carrieri MP, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y. Drug Alcohol Depend; 2000 Jul 01; 60(1):51-4. PubMed ID: 10821989 [Abstract] [Full Text] [Related]
15. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C, Muñoz A. Clin Infect Dis; 2007 Aug 01; 45(3):370-6. PubMed ID: 17599317 [Abstract] [Full Text] [Related]
16. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Spire B, Lucas GM, Carrieri MP. Int J Drug Policy; 2007 Aug 01; 18(4):262-70. PubMed ID: 17689374 [Abstract] [Full Text] [Related]
17. Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment. Backmund M, Reimer J, Meyer K, Gerlach JT, Zachoval R. Clin Infect Dis; 2005 Apr 15; 40 Suppl 5():S330-5. PubMed ID: 15768343 [Abstract] [Full Text] [Related]
18. Factors associated with methadone maintenance therapy use among a cohort of polysubstance using injection drug users in Vancouver. Kerr T, Marsh D, Li K, Montaner J, Wood E. Drug Alcohol Depend; 2005 Dec 12; 80(3):329-35. PubMed ID: 15964714 [Abstract] [Full Text] [Related]
19. Factors associated with client-reported HIV infection among clients entering methadone treatment. MacGowan RJ, Fichtner RR, Swanson N, Collier C, Kroliczak A, Cole G. AIDS Educ Prev; 1997 Jun 12; 9(3):205-17. PubMed ID: 9241388 [Abstract] [Full Text] [Related]
20. HIV infection as a predictor of methadone maintenance outcomes in Chinese injection drug users. Zhao L, Holzemer WL, Johnson M, Tulsky JP, Rose CD. AIDS Care; 2012 Jun 12; 24(2):195-203. PubMed ID: 21780984 [Abstract] [Full Text] [Related] Page: [Next] [New Search]